ClinicalTrials.gg
RecruitingNCT07081282Updated Jul 23, 2025

Precision Stratification for Frailty and Cognitive Decline

An interventional study of Care4Senior mobile Application, Intensive Aerobic Resistance Training and Brain Health (CIRTAB) and Centre-Based Exercise Health Session in Frailty and Cognitive Decline, sponsored by National University of Singapore. Recruiting at 1 site in Singapore. Open to participants aged 60 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-23.

Sponsored by National University of Singapore · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
252
Allocation
Randomized
Ages
60 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Frailty with a site in Singapore — 12 open to participants now, 13 under way, none of them phase 3. Frailty · Singapore.

Planned enrollment
7th of 21
252 · median 140
Started
2025
with 4 others
No phase
20 of 28
9 open now
Primary completion
2027-01
later than 6 of 12 live
Registered
22nd of 28
by date
Lead sponsor
6 of 28
National University of Singapore

Among the 28 studies in Frailty with a site in Singapore, this one is the 7th largest by planned enrollment of the 21 interventional ones that give a count, is one of 5 that started in 2025, is one of 20 with no phase, reaches primary completion later than 6 of the 12 other live ones, and was the 22nd registered.

Frailty

1,291 studies on the registry are indexed under Frailty; 454 are open to participants now.

Browse Frailty studies →

Open to participants now

12 of the 28 studies in Frailty with a site in Singapore are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →

Who these studies take

Of the 299 Frailty studies recruiting now, 235 (79%) set no upper age limit and 10 (3%) stop at 75 or younger; 7 take children under 18; 66 take healthy volunteers.

This study: 60 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Frailty with a site in Singapore, or all of them as a file.
02

Study summary

The Care4Senior mobile Application, Intensive Aerobic Resistance Training and Brain Health (CIRTAB) trial aim to test the effectiveness of an exercise, cognitive and lifestyle intervention amongst older adults over a 12-weeks trial period to prevent frailty and promote social bonding.

Read the detailed description

In the Care4Senior mobile Application, Intensive Aerobic Resistance Training and Brain Health (CIRTAB) trial, participants will use the Care4Seniors 2.0 mobile application, in which physical and cognitive exercises will be provided to participants using this digital technology. Weekly in-person group exercise and cognitive sessions will also be conducted to prevent frailty, promote social bonding, as well as reduce social isolation and loneliness.

In the long term, this new service model has the potential to transform care, contain healthcare cost inflation and increase the efficiency of the lean manpower. It will translate knowledge into practice, resulting in impactful outcomes such as better self-management and healthy longevity. The CIRTAB program will raise the awareness of health behaviour, thus attracting more older adults to engage in preventive health and thus better prepare them for healthy ageing.

03

Conditions studied

  • Frailty
  • Cognitive Decline
04

Who can participate

Ages eligible
60 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Older Adults Aged 60 to 85 years old
  2. Living in the community
  3. Formally diagnosed with at least one chronic disease
  4. Able to communicate in either English or Mandarin

Exclusion criteria

Exclusion Criteria:

  1. Severe vision or hearing impairment
  2. Diagnosed with severe cognitive impairment (e.g. dementia)
  3. Diagnosed with severe psychiatric disorders (e.g. psychotic disorders, major depressive disorder)
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
252 participants (estimated)

Study arms

  • Experimental
    Intervention Arm

    Participants will receive the CIRTAB intervention three times each week over 12-weeks.

    Behavioral: Care4Senior mobile Application, Intensive Aerobic Resistance Training and Brain Health (CIRTAB)

  • Active comparator
    Active Control

    Participants will receive once in centre-based exercise health programme each week over 12-weeks.

    Behavioral: Centre-Based Exercise Health Session

  • No intervention
    Control

    Participants will not participate in any exercise-related or brain health-related research studies or centre-based programme during trial period.

Interventions

  • BehavioralCare4Senior mobile Application, Intensive Aerobic Resistance Training and Brain Health (CIRTAB)

    Care4Senior mobile Application, Intensive Aerobic Resistance Training and Brain Health (CIRTAB)

    Also known as: CIRTAB

  • BehavioralCentre-Based Exercise Health Session

    Participants will receive one time centre-based exercise health programme each week.

06

What researchers measure

Primary outcomes

  1. Frailty Status: - Edmonton Frailty Scale - Clinical Frailty Scale - Oral Frailty Index-8

    These measurements will be conducted by researchers at three timepoints - baseline, immediate post-intervention and 6 months post-intervention. The Edmonton Frailty Scale ranges from a minimum score of 0 (not frail) to a maximum score of 17 (severely frail), with higher scores indicating greater frailty. The Clinical Frailty Scale ranges from 1 (very fit) to 9 (terminally ill), with higher scores indicating greater frailty. The Oral Frailty Index-8 (OFI-8) ranges from a minimum score of 0 to a maximum of 8, with higher scores indicating greater oral frailty.

    Time frame: From enrollment to the end of treatment at 12 weeks.

  2. Presence of Sarcopenia: - Strength, Assistance with walking, Rise from a chair, Climb stairs, and Falls (SARC-F) Questionnaire

    These measurements will be conducted by researchers at three timepoints - baseline, immediate post-intervention and 6 months post-intervention. The SARC-F Questionnaire ranges from a minimum score of 0 to a maximum of 10, with higher scores indicating greater risk of sarcopenia. A score of 4 or more suggests sarcopenia.

    Time frame: From enrollment to the end of treatment at 12 weeks.

  3. Presence of Cognitive Decline: - Montreal Cognitive Assessment - Symbol Digit Modalities Test - Cognitive Predictive Risk Score (developed from previous study)

    These measurements will be conducted by researchers at three timepoints - baseline, immediate post-intervention and 6 months post-intervention. The Montreal Cognitive Assessment (MoCA) is a screening tool for mild cognitive impairment, scored out of 30 points, with higher scores indicating better cognitive function. The Symbol Digit Modalities Test (SDMT) assesses attention, processing speed, and visual-motor coordination, typically scored by the number of correct symbol-digit matches in 90 seconds, with higher scores indicating better performance. The total score for SDMT is 110. The Cognitive Predictive Risk Score developed from previous study stratify the participants into those with high risk of cognitive decline and those with low risk of cognitive decline.

    Time frame: From enrollment to the end of treatment at 12 weeks.

  4. Immunological Biomarkers: - C1q (complement component 1q) - IL-6 (Interleukin-6)

    These measurements will be conducted by researchers at two timepoints - baseline and immediate post-intervention. The C1q levels typically range from 70 to 180 mg/L, with lower values indicating worsening immune function. The IL-6 levels normally range from 0 to 7 pg/mL, with higher values indicating increased inflammation.

    Time frame: From enrollment to the end of treatment at 12 weeks.

  5. Skeletomuscular Biomarkers: - IGF-1 (Insulin-like Growth Factor-1) - Myostatin

    These measurements will be conducted by researchers at two timepoints - baseline and immediate post-intervention. The IGF-1 levels may range from 100 to 300 ng/mL, with lower levels associated with possible growth hormone deficiency. The Myostatin levels in serum range between 1 to 5 ng/mL, with higher levels associated with reduced muscle mass.

    Time frame: From enrollment to the end of treatment at 12 weeks.

Secondary outcomes

  1. Self-Care Ability - Self-Care of Chronic Illness Inventory (SCCII)

    A generic measure designed to assess the process of self-care used by individuals with a variety of chronic conditions. It consists of 30 items that can be rated using 5-point Likert scale. There are four subdomains including self-help behavior, symptom management, health seeking behavior and self-care confidence. The minimum score is 28 and maximum score is 150. The higher the score, the better the self-care abilities.

    Time frame: From enrollment to the end of treatment at 12 weeks.

  2. Physical Activity Level - Global Physical Activity Questionnaire (GPAQ)

    The GPAQ measures physical activity in Metabolic Equivalent of Task (MET) minutes per week, with 0 MET-minutes/week as the minimum (no activity) and no theoretical upper limit. The Global Physical Activity Questionnaire (GPAQ) does not have a fixed minimum or maximum score, the higher the GPAQ score, the greater the level of physical activity.

    Time frame: From enrollment to the end of treatment at 12 weeks.

  3. Physical Function - Short Physical Performance Battery (SPPB)

    The SPPB is a standardised tool designed to assess lower limb function and overall physical performance in older adults. It has a minimum score of 0 and a maximum score of 12, with higher scores indicating better lower extremity function and physical performance.

    Time frame: From enrollment to the end of treatment at 12 weeks.

  4. Intrinsic Capacity - World Health Organization (WHO) Integrated Care for Older People (ICOPE) tool

    The WHO ICOPE tool comprise nine domains test on cognitive decline, limited mobility, malnutrition, visual impairment, hearing loss, depressive symptoms, social care and support, carer support and urinary incontinence. Any failure or no to each domain will lead to a suggested pathway as per WHO. There is no fixed minimum or maximum scores, the lower the number of flagged areas, the better the intrinsic capacity.

    Time frame: From enrollment to the end of treatment at 12 weeks.

07

Study locations

1 of 1 sites recruiting
  • Active Ageing Centres Under Changi General Hospital's Community Health Team Cluster (East Region)
    Singapore, Singapore
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Jan 2027, 18 months after the start.

Of 514 non-industry interventional studies with no phase under Frailty, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 39. This study's planned 18 months is below that.

Counting every sponsor, half of 519 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2025
First posted
Jul 23, 2025
StartActual
Jul 1, 2025
Primary completionEst.
Jan 31, 2027
CompletionEst.
May 31, 2027
Last update
Jul 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07081282
Responsible party
Vivien Xi WU, PhD (Assistant Professor, National University of Singapore) — Principal investigator
First posted
Jul 23, 2025
Start date
Jul 1, 2025
Primary completion
Jan 31, 2027 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Jul 23, 2025

Study contacts

Vivien Dr Wu
Contact
vivien.wu@nus.edu.sg
+6566012756
Delphine Ms Chen
Contact
e0002650@u.nus.edu

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion